Novel therapeutic approaches to gastric and duodenal ulcers: an update

Bibliography

• SOLL AH: Gastric, duodenal and stress ulcer. In:Gastro- intestinal Diseases: Pathophysiology/Diagnosis/Manage-ment (Edition 5). Sleisenger M, Fordtran J (Eds.), WB Saunders, Philadelphia, USA (1993)580–679.
   Google Scholar
• •This is a good general review of acid peptic diseases.
   Google Scholar
• GRAHAM DY, LEW GM, KLEIN PDet al: Effect of treatment of Helicobacer pylori infection on the long-term recurrence of gastric or duodenal ulcer: A randomized, controlled study.Ann. Intern. Med. (1992) 116:705–708.
   PubMed Web of Science ®Google Scholar
• •This study was a most definitive investigation, which linked ulcer recurrence toH pylori infection.
   Google Scholar
• TYTGAT GNJ, RAUWS EAJ: Campylobacter pylori and its role in peptic ulcer disease.Gastroenterol. Clin. North Am. (1990) 19:183–196.
   PubMed Web of Science ®Google Scholar
• DAJANI EZ, AGRAWAL NM: Prevention and treatment of ulcers induced by nonsteroidal anti-inflammatory drugs.J. Assoc. Acad. Minor. Phys. (1992) 3:142–148.
   PubMedGoogle Scholar
• AGRAWAL NM, DAJANI EZ: Drug induced ulcerogenesis. In:Gastrointestinal Pharmacology and Therapeutics. G Freemanet al (Eds.), Lippincott-Raven Publisher, Philadel-phia, USA (1997):55–63.
   Google Scholar
• •This paper reviews NSAIDs as one of the major causes of drug-induced ulcers and discusses treatment options.
   Google Scholar
• DAJANI EZ, AGRAWAL NM: Selective COX-2 inhibitors and gastrointestinal mucosal injury: Pharmacological and therapeutic considerations.J. Assoc. Acad. Minor. Phys. (In Press).
   Google Scholar
• SMOOT DT, HAMILTON FA: Summary of the National Institutes of Health Consensus Development Confer-ence on Helicobacter pylori.Gastrointest. Dis. Today (1995) 4:1–10.
   Google Scholar
• VELDHUYZEN VAN ZANTEN SJ, SHERMAN PM: Helico-bacter pylori infection as a cause of gastritis, duodenal ulcer, gastric cancer and nonulcer dyspepsia: a systematic overview.Can. Med. Assoc. J. (1994) 150:177–185.
   Web of Science ®Google Scholar
• DUNN BE: Pathogenic mechanisms of Helicobacter pylori.Gastroenterol. Clin. North Am. (1993) 22:43–57.
   PubMed Web of Science ®Google Scholar
• LEE A, MITCHELL H: Basic bacteriology of H. pylori: H. pylori colonization factors. In:Helicobacter pylori: Basic Mechanisms to Clinical Cure. Hunt RH, Tytgat GNJ (Eds.), Kluwer Academic Publishers, Dordrecht, Germany (1994):59–72.
   Google Scholar
• DORE MP, GRAHAM DY: Pathogenesis of duodenal ulcer disease: the rest of the story.Baillieres Best Pract. Res. Clin. Gastroenterol. (2000) 14:97–107.
   PubMed Web of Science ®Google Scholar
• WALSH JH, PETERSON WL: The treatment of Helico-bacter pylori infection in the management of peptic ulcer disease.N Engl. J. Med. (1995) 33:984–991.
   Google Scholar
• GRAHAM DY, RAKEL RE, FENDRICK AMet al.: Practical advice on eradicating Helicobacter pylori infection.Postgrad. Med. (1999) 105:137–140.
   Google Scholar
• GRAHAM DY: Helicobacter pylori: its epidemiology and its role in duodenal ulcer disease.J. Gastroenterol. Hepatol. (1991) 6:105–113.
   PubMed Web of Science ®Google Scholar
• PETRERSON WL: Helicobacter pylori and peptic ulcer disease.N Engl. J. Med (1991) 324:1043–1048.
   PubMed Web of Science ®Google Scholar
• GRAHAM DY, LEW GM, EVANS DGet al.: Effect of triple therapy (antibiotics plus bismuth) on duodenal ulcer healing. A randomized controlled trial.Ann. Intern. Med. (1991) 115:266–269.
   Google Scholar
• MARSHALL BJ, GOODWIN CS, WARREN JRet al.: Prospective double-blind trial of ulcer relapse after eradication of Campylobacter pylori.Lancet (1988) 2:1439–1442.
   Google Scholar
• •This study represents the first documented clinical investiga-tion linking ulcer recurrence toH. pylori.
   Google Scholar
• WOLFE MM, LICHTENSTEIN DR, SINGH G: Gastrointes-tinal toxicity of nonsteroidal anti-inflammatory drugs.N. Engl. J. Med. (1999) 340: 1888-1899.
   Google Scholar
• DAJANI EZ, AGRAWAL NM: NSAID-induced gastrointes-tinal damage in the elderly.Intern. Med. Specialist (1990) 11:91–110.
   PubMedGoogle Scholar
• RIENDEAU D, CHARLESON S, CROMLISH Wet al.: Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays.Can. J. Physiol. Pharmacol. (1997) 75:1088–1095.
   Google Scholar
• WARNER TD, GIULIANO F, VOJNOAVIC Iet al.: Nonsteroid drugs selective for cyclo-oxygenase-1 rather cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in-vitro analysis.Proc. Natl. Acad. ScL USA (1999) 96:7563–7568.
   Google Scholar
• SACHS G: Proton pump inhibitors and acid-related diseases.Pharmacotherapy (1997) 17:2–37.
   Web of Science ®Google Scholar
• •This review presents a broad pharmacological discussion of PPIs.
   Google Scholar
• WURST W, HARTMANN M: Current status of acid pump antagonists (reversible PPIs).Yale J. Biol. Med. (1996) 69:233–243.
   PubMed Web of Science ®Google Scholar
• BARCLAY ML, BEGG EJ, ROBSON RAet al.: Lansoprazole pharmacokinetics differs in patients with oesoph-agitis compared to healthy volunteers.Aliment. Pharmacol. Then. (1999) 13:1215–1219.
   Google Scholar
• DEKKERS CP, BEKER JA, THJODLEIFSSON Bet al.: Comparison of rabeprazole 20 mgversus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicenter study.Aliment. Pharmacol. Then. (1999) 13:179–186.
   Google Scholar
• THJODLEIFSSON B, COCKBURN I: Review article: rabeprazole's tolerability profile in clinical trials.Aliment. Pharmacol Then. (1999) 13 (Suppl. 5):17–23.
   Google Scholar
• PARSONS ME: Pantoprazole, a new proton pump inhibitor, has a precise and predictable profile of activity.Eur. J. Gastroenterol Hepatol. (1966) 8\(Suppl. 1):S15–S20.
   Google Scholar
• MARTINEK J, BLUM AL, STOLTE Met al.: Effects of pumaprazole (BY 841), a novel reversible proton pump antagonist and omeprazole, on intragastric acidity before and after cure of Helicobacter pylori infection.Aliment. Pharmacol. Then. (1999) 13:27–34.
   Google Scholar
• CHUNG SY, HAN KS, SHON SKet al.: Pharmacokineticsof a new proton pump inhibitor, YJA-20379-8, after intravenous and oral administration to rats with streptozotocin-induced diabetes mellitus.J. Pharm. Pharmacol. (1999) 51:929–934.
   Google Scholar
• HASSAN-ALIN M, ROHSS K, ANDERSSEN T, NYMAN L: Pharmacokinetics of esomeprazole after oral and © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (2000) 9(7) intravenous administration of single and repeated doses to healthy subjects.Gastroenterology (2000) 118 (Suppl. 2):A16 (Abstract).
   Google Scholar
• BRUNTON LL: Agents for control of gastric acidity, and treatment of peptic ulcers. In:Goodmans and Gilman's The Pharmacological Basis of Therapeutics (Edition 8). Goodman AG, Rail WL, Nies AS, Taylor O, (Eds.), Pergamon, New York, USA (1990902–904.
   Google Scholar
• KROMER W: Similarities and differences in the proper-ties of substituted benzimidazoles: A comparison between pantoprazole and related compounds.Digestion (1995) 56:443–454.
   PubMed Web of Science ®Google Scholar
• FENNERTY MB, CASTELL DO, FENDRICK AMet al.: The diagnosis and treatment of gastroesophageal reflux disease in a managed care environment.Arch. Intern. Med. (1996) 156:477–484.
   Google Scholar
• DAJANI EZ: Gastroesophageal reflux disease (GERD): Pathophysiological and pharmacological considera-tions.J. Assoc. Acad. Minor. Phys. (1999) 11(1):7–11.
   Google Scholar
• SCHEIMAN J, ISENBERG J: Agents used in the prevention and treatment of nonsteroidal anti-inflammatory drug-associated symptoms and ulcers.Am. J. Med. (1998) 105:32S–385.
   Google Scholar
• YOEMANS ND, TULASSAY Z, JUHASZ Let al.: A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs. Acid Suppression Trial: Ranitidineversus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group.N Engl. J. Med. (1998) 338:719–726.
   Google Scholar
• •This study clearly supports a beneficial role of omeprazole for the treatment of NSAID-associated ulcers.
   Google Scholar
• HAWKEY CJ, KARRASCH JA, SZEZEPANSKI Let al.: Omeprazole compared with misoprostol for ulcers associated with nonsteroidal anti-inflammatory drugs. Omeprazoleversus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group.N Engl. J. Med. (1998) 338:727–734.
   Google Scholar
• •This study compared the efficacy of misoprostol with omeprazole for the treatment of NSAID-associated ulcers.
   Google Scholar
• ANAND BS, GRAHAM DY: Ulcer and gastritis.Endoscopy (1999) 31:215–225.
   PubMed Web of Science ®Google Scholar
• SILVERSTEIN FE, GEIS GS, STRUTHER BJet al.: Misoprostol reduces serious gastrointestinal compli-cations in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double blind, placebo-controlled trial.Ann. Intern. Med. (1995) 123:241–249.
   Google Scholar
• •This is the first major outcome study, which demonstrated the beneficial action of misoprostol for the prevention of NSAID-induced ulcers.
   Google Scholar
• AGRAWAL NM, AZIZ K: Prevention of gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs.J. Rheumatol. (1998) 51 (Suppl.):17–20.
   Google Scholar
• FRESTON J: Long-term acid control and proton pump inhibitors: Interactions and safety issues in perspec-tives.Am. J. Gastroenterol. (1997) 92:518S–557S.
   Google Scholar
• REILLY JP: Safety profile of the proton pump inhibi-tors.Am. J. Health Syst. Pharm. (1999) 56:S11–S17.
   PubMed Web of Science ®Google Scholar
• KROMER W, HORBACK S, LUHMANN R: Relative effica-cies of gastric proton pump inhibitors: their clinical and pharmacological basis.Pharmacology (1999) 59:57–77.
   PubMed Web of Science ®Google Scholar
• LEW EA: Pharmacokinetic concerns in the selection of anti-ulcer therapy.Aliment. Pharmacol. Ther. (1999) 13 (Suppl. 5):11–16.
   Google Scholar
• HUMPHRIES TJ, MERRITT GJ: Drug interactions with agents to treat acid-related diseases.Aliment. Pharmacol. Ther. (1999) 13 (Suppl. 3):18–26.
   Google Scholar
• BYRNE MF, MURRAY FE: Formulary management of proton pump inhibitors.Pharmacoeconomics (1999) 16:225–246.
   PubMed Web of Science ®Google Scholar
• HOWDEN CW: Use of proton-pump inhibitors in complicated ulcer disease and upper gastrointestinal bleeding.Am. J. Health Syst. Pharm. (1999) 56(23 Suppl. 4):S5–S11.
   Google Scholar
• ARAKAWA T, KOBAYASHI K, YOSHIKAWA T, TARNAWSKI A: Rebamipide: Overview of its mechanisms of action and efficacy in mucosal protec-tion and ulcer healing.Dig. Dis. Sci. (1998) 43 (Suppl. 9):5S–13S.
   Google Scholar
• •The investigation reviewed in details the mechanisms of the mucosal protective and anti-ulcer actions of rebamipide.
   Google Scholar
• ITO M, TANAKA T, SUZUKI Y: Effect of N-(3-aminopropiony1)-L- histidanto zinc (Z103) on healing and hydrocortisone-induced relapse of acetic acid ulcers in rats with limited food intake-time.Jpn. Pharmacol. (1990) 52:513–521.
   PubMedGoogle Scholar
• ARAKAWA T, SATOH H, NAKAMURA Aet al.: Effect ofzinc-L-carnosine on gastric mucosal and cell damage caused by ethanol in rats.Dig. Dis. Sci. (1990) 35:559–566.
   Google Scholar
• KATO S, NISHIWAKI H, KONAKA A, TAKEUCHI K: Mucosal ulcerogenic action of monochloramine in rat stomachs. Effects of polaprezinc and sucralfate.Dis. Sci. (1997) 42:2156–2163.
   PubMed Web of Science ®Google Scholar
• KONTUREK JW, HENGST K, KONTUREK SJ, DOMSCHKE W: Epidermal growth factor in gastric ulcer healing by nocloprost, a stable prostaglandin E2 derivative.Scand. j Gastroenterol (1997) 32(10)980–984.
   Google Scholar
• SONTAG SJ. Clinical Review. Guilty as charged: Bugs and drugs in gastric ulcer.Am. J. Gastroenterol. (1997) 92:1255–1261.
   PubMed Web of Science ®Google Scholar
• •This is an excellent review presenting the role ofH pylori and NSAIDs in the pathogenesis of gastric ulcers.
   Google Scholar